Immunogen, Inc. (NASDAQ:IMGN) shares traded 0.20% higher at $29.71 on Wall Street last session.
In accordance with the data, 14 analysts cover Immunogen, Inc. (NASDAQ:IMGN). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $31.26 and a low of $19.00, we find $31.00. Given the previous closing price of $29.65, this indicates a potential upside of 4.55 percent. IMGN stock price is now 71.00% away from the 50-day moving average and 116.27% away from the 200-day moving average. The market capitalization of the company currently stands at $7.95B.
It has been rated a hold by 11 analysts and a buy by 3. Brokers who have rated the stock have averaged $29.48 as their price target over the next twelve months.
With the price target enhanced from $25 to $31, Guggenheim Downgraded its rating from Buy to Neutral for Immunogen, Inc. (NASDAQ: IMGN).
In other news, Wingrove Theresa, SVP OF REGULATORY AFFAIRS sold 164,424 shares of the company’s stock on Nov 30. The stock was sold for $4,760,075 at an average price of $28.95. Upon completion of the transaction, the SVP OF REGULATORY AFFAIRS now directly owns 2,811 shares in the company, valued at $83514.81. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 30, Director Peterson Kristine sold 20,000 shares of the business’s stock. A total of $578,000 was realized by selling the stock at an average price of $28.90. Insiders disposed of 4,269,035 shares of company stock worth roughly $126.83 million over the past 1 year. A total of 2.56% of the company’s stock is owned by insiders.
Immunogen, Inc. (NASDAQ: IMGN) opened at $29.80 on Tuesday. During the past 12 months, Immunogen, Inc. has had a low of $3.61 and a high of $29.93. As of last week, the company has a debt-to-equity ratio of 0.20, a current ratio of 5.70, and a quick ratio of 5.65. The fifty day moving average price for IMGN is $17.37 and a two-hundred day moving average price translates $13.74 for the stock.
The latest earnings results from Immunogen, Inc. (NASDAQ: IMGN) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at $0.1, beating analysts’ expectations of $0.04 by 0.06. This compares to -$0.31 EPS in the same period last year. The net profit margin was -25.56% and return on equity was -19.88% for IMGN. The company reported revenue of $113.42 million for the quarter, compared to $15.38 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 637.72 percent. For the current quarter, analysts expect IMGN to generate $129.47M in revenue.
